Announcements Trials
Browse Landscape

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 272Observational 2

Sponsor

Cancer Type

Thoracic 18Dermatologic 11Gastrointestinal 7Head & Neck 6Genitourinary 6Breast 2Tumor-Agnostic 1Other 1CNS 1

Conditions

Triple Negative Breast Neoplasms 1Breast Neoplasms 1

Interventions

Surveys and Questionnaires 79Blood Specimen Collection 67palbociclib 40Trastuzumab 34Drug Therapy 30Letrozole 29Anastrozole 27Radiotherapy 26Immunohistochemistry 26Mastectomy, Segmental 22Amplified Fragment Length Polymorphism Analysis 22Fulvestrant 21Biopsy 21exemestane 20Tamoxifen 20Interviews as Topic 20Gene Expression Profiling 20Magnetic Resonance Spectroscopy 19ribociclib 18Specimen Handling 18Mastectomy 18Neoadjuvant Therapy 17Paclitaxel 16High-Energy Shock Waves 16Capecitabine 16trastuzumab deruxtecan 15Mammography 15Psychiatric Rehabilitation 14Polymerase Chain Reaction 13Observation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × pembrolizumab × Breast × Clear all
NCT05916755 2023-06-23

PORTRAIT

Vall d'Hebron Institute of Oncology

Recruiting
100 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04683445 2020-12-24

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Unknown
80 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡